Publication | Open Access
A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
22
Citations
23
References
2023
Year
Our data demonstrate the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bifunctional single-molecule therapeutic strategy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1